bring global innov china oncolog focu
hutchison china meditech chi-m noteworthi achiev includ
landmark approv launch elun fruquintinib china mcrc
continu matur tyrosin kinas inhibitor tki pipelin multipl
asset either approach china global registr trial signific
invest build us infrastructur support global innov
pipelin bring progress steadi stream clinic catalyst
savolitinib nsclc data march continu
valu chi-m
share issu
ebitda includ equiti earn equiti investe
elun fruquintinib pioneer product elun launch partner eli
lilli novemb gener revenu first five week solid earli
sign clinic accept boost confirm reimburs
negoti secur potenti nation drug reimburs list ndrl inclus
updat pursu develop front phase
frutiga gastric cancer interim analysi immin combin
studi plan decemb eli lilli deal amend provid chi-m
greater control plan includ life cycl initi increas
potenti elun market opportun share deal econom
savolitinib take centr stage chi-m aacr matur data phase
ib/ii global tatton savolitinib osimertinib combin nsclc trial
schedul present march plenari session also
includ interim data china registr studi savolitinib monotherapi
exon nsclc latter studi complet enrol
subject posit result enabl china nda file outsid china
savannah phase ii savolitinib osimertinib combin trial c-met
refractori nsclc due read potenti
pivot nsclc combin trial announc later
hutchison china meditech hong
kong headquart biopharma
establish commerci platform
china divers pipelin
discov in-hous
develop china
 invest grow portfolio progress result met exceed
expect guidanc centr spend
adjust non-gaap net cash flow reflect grow
invest innov pipelin driver chi-m futur
growth initi address china oncolog opportun longer-
term global innov pipelin
maintain valuat valu chi-m use
dcf-base sotp approach includ rnpv model clinic pipelin
current valuat
influenc variou share price catalyst next month
chi-m wealth opportun
mark sever import achiev hutchison china meditech
chi-m anoth critic year compani rich vein
news flow exhibit sever clinic studi due produc interim
matur result variou new trial initi includ global proof
concept studi inhibitor inhibitor
howev focu investor larg chi-m two valuabl
asset fruquintinib elun savolitinib burgeon us
infrastructur global innov pipelin continu valu chi-m
expect revisit
assumpt clinic regulatori commerci catalyst unlock valu
preliminari phase ii monotherapi data c-met exon mutations/delet nsclc china
full phase ii data global tatton studi global
interim phase frutiga analysi futil fruquintinib paclitaxel combo gastric cancer
china top line data
initi phase i/ib studi indol nhl us/eu
initi phase i/ib studi indol nhl us/eu
init phase ii/iii chemo-refractori biliari tract cancer china
preliminari phase ii viktori data savolitinib docetaxel combo c-met mutat gastric
interim analysi phase sanet-ep china non-pancreat net
phase i/ib proof concept data indol nhl china
interim analysi phase sanet-p china pancreat net
initi phase ii/iii trial colorect cancer us
releas prescript sale perform data mcrc china interim result
plan phase ii/iii studi lung cancer announc global
initi us develop fruquintinib surufatinib combin
still earli launch phase
elun fruquintinib first domest discov develop
innov oncolog compound approv china follow launch mcrc
last novemb elun show solid earli sign clinic accept
first five week market gener revenu chi-m
broken product purchas manufactur royalti
end-us sale partner manag also
mean patient pay
potenti inclus nrdl
catalys patient access
drive higher volum
potenti china
confirm end-januari ie first nine week market
patient receiv elun therapi
elun current out-of-pocket drug price rmb per
cycl equival although domest patient access programm
pap essenti limit pateint cost treatment maximum three
cycl pap design ensur broad avail reimburs
discuss on-going
chi-m focus ensur patient access increas
penetr mcrc set drive sale volum rather
sole price negoti secur nation drug reimburs list ndrl
inclus potenti updat pursu believ strong
potenti elun futur inclus ndrl given preced set
list domest develop drug apatinib gastric cancer
anlotinib nsclc
develop front interim analysi futil phase
frutiga trial gastric cancer immin combin
studi plan part first wave life cycl indic lci chi-
med pursuit develop facilit amend
collabor announc decemb amend provid chi-m
greater control china plan includ lci exchang assum
 fund amend term shown exhibit
develop cost paid lilli
develop cost paid chi-m
regulatori approv mileston paid chi-m
royalti payment paid chi-m
co-promot right china provinc
co-promot servic fee paid chi-m net sale
hutchison china meditech note per china base total elun sale china trigger first
launch expect trigger china launch anti-vegf mab cyramza ramucirumab
elun fruquintinib core
china oncolog global
fruquintinib core asset china oncolog global innov
deal amend expand potenti elun market opportun china
coupl potenti co-promot right significantli
improv chi-m share deal econom also leverag chi-m
commerci acumen provid cornerston product nascent oncolog
commerci organis current expand end-
fruquintinib also one five global innov clinic asset
except savolitinib partner astrazeneca sold global
elun current chi-m valuabl china asset contribut
chi-m valuat
present
potenti first china approv
exon nsclc
tatton data inform global
registr strategi nsclc
abstract current
savolitinib clinic data determin direct
savolitinib develop prioritis non-smal cell lung cancer nsclc
chi-m partner astrazeneca data two key nsclc trial
present trial critic determin potenti
acceler launch china monotherapi exon nsclc
global develop timelin posit savolitinib/osimertinib
combin refractori nsclc
read complet data set china singl arm phase ii studi
exon nsclc establish potenti acceler approv
savolitinib monotherapi indic enrol track complet
data read expect agre efficaci threshold
met nda could file potenti china approv
data review dose expans part phase ib/ii tatton studi
tatton coupl outcom regulatori discuss
determin pivot trial design dose global savolitinib osimertinib
osimertinib c-met refractori nsclc could enabl us
approv initi decemb read howev
chi-med/astrazeneca indic anticip announc plan
potenti pivot combin trial later year strategi
run two global trial parallel two nsclc target patient popul
breakthrough therapi design btd potenti increas probabl
combin reach market rapidli believ savolitinib could
receiv fda approv combin osimertinib earlier
initi data china phase ii studi exon nsclc matur data
 cohort global phase ib/ii tatton combin studi
present oral march plenari session entitl challeng
nsclc resist mek abstract current
embargo titl releas
preliminari efficaci safeti result savolitinib treat patient
pulmonari sarcomatoid carcinoma psc type nsclc
tatton phase ib expans cohort osimertinib plu savolitinib patient
egfr-mut met-amplifi nsclc progress prior
tatton phase ib expans cohort osimertinib plu savolitinib patient
egfr-mut met-amplifi nsclc progress prior third-
addit biomark analysi tatton studi present
poster april detect met-medi egfr tyrosin kinas inhibitor tki
resist advanc non-smal cell lung cancer nsclc biomark analysi
tatton studi
current valu savolitinib
valuat
valu chi-m use sum-of-the-part methodolog incorpor
earnings-bas multipl commerci platform rnpv model
innov platform valuat remain equival per
per share
exhibit provid high-level overview rel import variou
asset valuat detail breakdown valuat found
februari initi valuat broadli split innov
platform contribut commerci platform
add
exhibit rel contribut chi-m programm valuat
scope materi uplift
valuat progress continu
employ conserv assumpt throughout model therefor
number increment improv base case scenario notabl within
innov platform could result sizeabl uplift valuat
addit visibl late-stag clinic programm increas
rich news flow come year suggest signific upsid
potenti multipl catalyst expect come month
triniti delta result least line
suffici cash resourc fund
activ
guidanc focus key
metric spend adjust
chi-m report result met beat expect group revenu
due implement
two-invoic accounting/book system alter domest china sale
report revenu growth jv
provid better reflect commerci platform perform
spend innov platform rose line
increas number later-stag clinic studi underway
translat attribut net loss rise group level
resourc remain strong avail decemb vs
consist cash cash equival short-term
invest unutilis bank facil addit
avail cash resourc held within non-consolid jv manag
confid support increas spend
least believ given clinic opportun would judici
issu addit debt model absenc
addit capit rais debt financ chi-m could attract
option compani given strength commerci oper broad
pipelin back implicit explicit ck hutchison
chi-m streamlin financi guidanc focus
import guidanc metric invest adjust group net cash flow
 expens expect fall within rang
adjust net cash outflow non-gaap exclud financ activ
anticip
estim chi-m invest
respect support grow number pivot studi
increas invest global innov
revis estim indic exhibit take account
result manag guidanc financi forecast shown
exhibit summari chang estim
exhibit summari financi
triniti deltayear-end decemb good oper profit tax earn equiti investe net incom incom attribut per share marginn/an/an/an/an/aunderli oper marginn/an/an/an/an/abal sheetcurr cash current plant equiti non-curr current non-curr statementsoper cash adjust oper cash work cash short term equiti cash financ cash increas rate start end cash end
triniti delta research limit tdrl firm refer number trade triniti delta appoint repres
equiti develop limit ed content report prepar sole responsibil iti tdrl
review independ verifi ed authoris regul fca whose refer number
ed act tdrl person respons provid protect provid client tdrl
advis person connect content report except extent requir applic abl law
includ rule fca owe duti care person lianc may place ed advic
recommend respect content report extent may applic law ed make
represent warranti person read report regard inform contain
prepar report tdrl use public avail sourc taken reason effort ensur fact state
herein clear fair mislead make guarante warranti accuraci complet inform
opinion contain herein provid updat fresh inform becom avail opinion chang
person relev person section section financi servic market act unit
kingdom act reli document content research client compani produc tdrl normal
commiss paid compani issuer financ research deem independ
defin fca object author state opinion report consid market
commun purpos fca rule prepar accord legal requir design promot
independ invest research subject prohibit deal ahead dissemin investm ent research
tdrl hold posit compani mention report although director employe consult tdrl
may hold posit compani mention tdrl impos restrict person deal tdrl might also provid servic
compani mention solicit busi
report provid relev person provid background inform subject matter note ocument
constitut form part constru offer sale purchas solicit invit
make offer buy sell secur may rise fall valu shall part form asi reli
connect contract commit whatsoev inform pro vide intend
manner whatsoev constru personalis advic self-certif investor complet free charg
www fisma org tdrl affili offic director employe ed liabl loss damag aris use
document maximum extent law permit
inform avail websit www trinitydelta org
